Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NasdaqGS - Delayed Quote USD

Inhibrx Biosciences, Inc. (INBX)

12.26
+0.28
+(2.34%)
At close: April 25 at 4:00:02 PM EDT
11.75
-0.51
(-4.16%)
Pre-Market: 4:07:30 AM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
Total Revenue
200
200
1,800
1,301
Operating Expense
331,648
331,648
221,021
116,624
Operating Income
-331,448
-331,448
-219,221
-115,323
Net Non Operating Interest Income Expense
-2,551
-2,551
-19,923
--
Other Income Expense
2,021,573
2,021,573
-580
1
Pretax Income
1,687,574
1,687,574
-239,724
-115,322
Tax Provision
2
2
3
3
Earnings from Equity Interest Net of Tax
--
--
-1,634
--
Net Income Common Stockholders
1,687,572
1,687,572
-241,361
-115,325
Diluted NI Available to Com Stockholders
1,687,572
1,687,572
-241,361
-115,325
Basic EPS
114.01
--
-16.95
-8.10
Diluted EPS
112.62
--
-16.95
-8.10
Basic Average Shares
14,802
--
14,241.18
14,241.18
Diluted Average Shares
14,984
--
14,241.18
14,241.18
Total Operating Income as Reported
-331,448
-331,448
-219,221
-115,323
Total Expenses
331,648
331,648
221,021
116,624
Net Income from Continuing & Discontinued Operation
1,687,572
1,687,572
-241,361
-115,325
Normalized Income
-333,923.60
-333,923.60
-241,361
-115,325
Interest Income
10,940
10,940
11,917
--
Interest Expense
13,491
13,491
31,840
--
Net Interest Income
-2,551
-2,551
-19,923
--
EBIT
1,701,065
1,701,065
-207,884
-115,323
EBITDA
1,703,350
1,703,350
-206,693
-114,098
Reconciled Depreciation
2,285
2,285
1,191
1,225
Net Income from Continuing Operation Net Minority Interest
1,687,572
1,687,572
-241,361
-115,325
Total Unusual Items Excluding Goodwill
2,021,498
2,021,498
--
--
Total Unusual Items
2,021,498
2,021,498
--
--
Normalized EBITDA
-318,148
-318,148
-206,693
-114,098
Tax Rate for Calcs
0
0
0
0
Tax Effect of Unusual Items
2.40
2.40
--
--
12/31/2022 - 6/4/2024

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ROIV Roivant Sciences Ltd.
11.01
+0.09%
 
ITOS iTeos Therapeutics, Inc.
7.35
-1.47%
 
PBYI Puma Biotechnology, Inc.
3.0000
-0.33%
 
KROS Keros Therapeutics, Inc.
14.21
-1.46%
 
KYMR Kymera Therapeutics, Inc.
33.26
-0.89%
 
IPHA Innate Pharma S.A.
1.9800
0.00%
 
HRMY Harmony Biosciences Holdings, Inc.
29.61
+0.61%
 
ORIC ORIC Pharmaceuticals, Inc.
5.10
-1.73%
 
RIGL Rigel Pharmaceuticals, Inc.
19.28
+1.15%
 
PBN.F Alterity Therapeutics Limited
0.0045
0.00%